Form 8-K - Current report:
SEC Accession No. 0001999371-25-017964
Filing Date
2025-11-17
Accepted
2025-11-17 07:05:34
Documents
14
Period of Report
2025-11-17
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_111725.htm   iXBRL 8-K 27360
2 PRESS RELEASE OF THE COMPANY, DATED NOVEMBER 4, 2025 ex99-01.htm EX-99.01 31428
6 GRAPHIC tonix.jpg GRAPHIC 4306
  Complete submission text file 0001999371-25-017964.txt   240507

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tnxp-20251117.xsd EX-101.SCH 3023
4 XBRL LABEL FILE tnxp-20251117_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE tnxp-20251117_pre.xml EX-101.PRE 22364
16 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_111725_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 251489299
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)